Get started
Author

Alex Chen

Observed names: A.P. Chen, Alex H Chen
ORCID: 0009-0003-5900-1892
Observed ORCID: 0009-0003-5900-1892
OpenAlex ID: A5000696561
Predicting the tumor microenvironment composition and immunotherapy response in non-small cell lung cancer from digital histopathology images
2024 · Sushant Patkar, Alex Chen, et al. · npj Precision Oncology · 40
PDF
NCI-MATCH Arms N & P: Phase II study of PI3K beta inhibitor GSK2636771 in patients (pts) with cancers (ca) with PTEN mutation/deletion (mut/del) or PTEN protein loss
2018 · F. Janku, O. Jegede, et al. · Annals of Oncology · 11
Ipatasertib in Patients with Tumors with AKT Mutations: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Sub-protocol Z1K
2022 · K. Kalinsky, W. Zihan, et al. · European Journal of Cancer · 7
PDF
Author Correction: Predicting the tumor microenvironment composition and immunotherapy response in non-small cell lung cancer from digital histopathology images
2025 · Sushant Patkar, Alex Chen, et al. · npj Precision Oncology · 3
PDF
Phase II study of sunitinib in tumors with c-KIT mutations: results from the NCI-MATCH ECOG-ACRIN trial (EAY131) subprotocol V
2022 · L. Gien, Z. Song, et al. · European Journal of Cancer · 3
PDF
Cancer Immunotherapy Using AIRE Conditioning of the Tumor Epitopeome
2024 · Richard Vile, Jose Pulido, et al. · Research Square · 1
77 Predicting the tumor microenvironment molecular composition to assess immunotherapy efficacy in non-small cell lung cancer from digital histopathology images
2024 · Alex H Chen, Sushant Patkar, et al. · Regular and Young Investigator Award Abstracts · 1
Identifying digital pathology imaging based biomarkers of checkpoint inhibitor response in non-small cell lung cancer.
2024 · Sushant Patkar, Alex Chen, et al. · Journal of Clinical Oncology · 1
Phase II trial of afatinib in patients with EGFR-mutated solid tumors excluding lung cancer: results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol A
2022 · K. Reckamp, Z. Song, et al. · European Journal of Cancer · 1
PDF
530P Phase II study of PI3K inhibitor copanlisib in cancer patients with deleterious PTEN mutations and retained PTEN protein expression: Results from the NCI-MATCH Trial (EAY131) sub-protocol Z1H
2021 · F. Janku, Z. Wei, et al. · Annals of Oncology · 1
PDF
Physician-guided deep learning model for assessing thymic epithelial tumor volume
2025 · Nirmal Choradia, Nathan Lay, et al. · Journal of medical imaging
Validation of HistoTME-predicted immune subtypes and immunotherapy outcomes using human interpretable features (HIFs) from H&E images in non-small cell lung cancer.
2025 · Meghdad Sabouri Rad, Palak Patel, et al. · Journal of Clinical Oncology
Works count: 12
Citation count: 69
H-index: 3
I10-index: 2
Year
Topic
Type